Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023
GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial Officer (CFO) Gustaf Albèrt, who has held the position since 2017 and since 2019 has also served as the company’s deputy CEO, has together with Isofol agreed to end his employment.
The information in the press release is intended for investors.
Gustaf Albèrt and Isofol have today come to an agreement that Gustaf will step down from his position as CFO and deputy CEO of Isofol Medical. The notice period will last until June 20, 2023 at the latest and during this time Gustaf will continue to serve in his role as CFO and deputy CEO.
”I would like to thank Gustaf for his great commitment and fine efforts during his time at the company. At Isofol, Gustaf contributed positively to the company’s development through his work in the management team and not least the extensive and demanding work to finance the company as well as secure its uplisting to Nasdaq Stockholm’s main market and the Mid Cap segment,” said Ulf Jungnelius, CEO of Isofol.
The company will refrain from an eventual recruiting of a new CFO until the Board of Directors has made a final decision about Isofol's future.
”The journey that Isofol has undergone since I assumed my role just over five years ago has been challenging and intense. Unfortunately, the AGENT study and all of the hard work that Isofol’s employees have invested did not lead to what we had hoped for. I would like to take the opportunity to thank all of my colleagues, Isofol’s management team and the company’s Board of Directors for a positive and rewarding collaboration,” said Gustaf Albèrt, CFO and deputy CEO för Isofol.
For further information, please contact
Isofol Medical AB (publ)
Jarl Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Telephone: +46 709-16 89 55
This information was submitted for publication, through the agency of the contact person set out above, at 13:30 CET on December 21, 2022.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology company that is developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol is focused on developing a drug for first-line treatment of advanced colorectal cancer (mCRC) and is trying to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Germany to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.